Physician profile
Truman Earl
NPI 1710034509
$10,571.34
in general payments reported to CMS, 2019-2025
13 companies · $172 in 2025
The $172 reported for 2025 was less than what a typical Transplant Surgery provider received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,608 · 2020: $521 · 2021: $960 · 2022: $409 · 2023: $135 · 2024: $1,766 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,406 · Food and Beverage: $668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,406.25 |
| Food and Beverage | $667.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,470.99 | 2019-2024 | |
| Eisai INC. | $2,186.92 | 2019 | |
| Baxter Healthcare | $1,095.03 | 2019-2025 | |
| Angiodynamics, INC. | $548.32 | 2019-2022 | |
| Boston Scientific Corporation | $419.37 | 2019-2020 | |
| Davol INC. | $265.59 | 2023-2024 | Phasix Mesh, Arista Ah Flexitip |
| Medtronic, INC. | $201.84 | 2021 | |
| Veloxis Pharmaceuticals, INC. | $124.91 | 2021 | |
| Kci USA, INC. | $110.26 | 2019-2022 | |
| Covidien LP | $68.33 | 2019 | |
| Merck Sharp & Dohme LLC | $37.86 | 2024-2025 | Prevymis |
| Mauna Kea Technologies, INC. | $26.63 | 2024 | |
| Smith+Nephew, INC. | $15.29 | 2023 | Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Truman Earl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.